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The authors wish to make the following correction to their paper [1].
The same image was mistakenly selected for Figures 2 and 3. The image became replaced as you
see in Figure 3 below.
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The authors wish to make the following correction to their paper [1].  
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Figure 2. CuMVtt-EDIII formulated in DOPS indices highest total IgG responses. The figure shows 
IgGs level of three different groups of mice vaccinated with EDIII alone formulated in phosphate-
buffered saline (PBS), with vaccine formulated by coupling EDIII to VLP (CuMVtt-EDIII) or 
formulating CuMVtt-EDIII plus DOPS adjuvant. The assessment was done with sera collected three 
weeks after each vaccination. The results were analyzed using GraphPad Prism software applied to 
assess the means of three groups by one-way analysis of variance (ANOVA). The values observed in 
Figure 2. CuMVtt-EDIII formulated in DOPS indices highest total IgG responses. The fig s IgGs
level of three different groups of mice vacc nated with EDIII alone formulated in phosphate-buffered
saline (PBS), with vaccine formulated by coupling EDIII to VLP (CuMVtt-EDIII) or formulating
CuMVtt-EDIII plus DOPS adjuvant. The assessment was done ith sera collected three weeks after
each vaccination. The results were analyzed using GraphPad Prism software applied to assess the
means of three groups by one-way analysis of variance (ANOVA). The values observed in the negative
control group (vaccinated with only PBS) were subtracted from the titers of the other experimental
groups. Note: * p < 0.01, ** p < 0.001, *** p < 0.0001.
Vaccines 2020, 8, 94; doi:10.3390/vaccines8010094 www.mdpi.com/journal/vaccines
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
8
0
0
0
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Vaccines 2020, 8, 94 2 of 2
Vaccines 2020, 8, 94 2 of 2 
 
the negative control group (vaccinated with only PBS) were subtracted from the titers of the other 
experimental groups. Note: * p < 0.01, ** p < 0.001, *** p < 0.0001. 
 
Figure 3. Subclasses of IgG. The figure shows the specific subclasses of IgG induced by each vaccine 
from samples collected three weeks after the third vaccination (Day 63). The group of mice vaccinated 
with only EDIII predominantly produced IgG1 while EDIII coupled to VLP (CuMVtt-EDIII) also 
induced IgG2a and IgG2b. When DOPS adjuvant was ad-mixed, this skewing towards IgG2a and b 
was even more pronounced. The results were analyzed using GraphPad Prism software applied to 
assess the means of three groups by one-way analysis of variance (ANOVA). The values observed in 
the negative control group were subtracted from the titers of the other experimental groups. Note: 
**  p < 0.001, *** p < 0.0001. 
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Figure 3. Subclasses of IgG. The figure shows the specific subclasses of IgG induced by each vaccine
from samples collected three weeks after the third vaccination (Day 63). The group of mice vaccinated
with only EDIII predominantly produced IgG1 while EDIII coupled to VLP (CuMVtt-EDIII) also
induced IgG2a and IgG2b. When DOPS adjuvant was ad-mixed, this skewing towards IgG2a and b
was even more pronounced. The results were analyzed using GraphPad Prism software applied to
assess the means of three groups by one-way analysis of variance (ANOVA). The values observed in
the negative control group were subtracted from the titers of the other experimental groups. Note: ** p
< 0.001, *** p < 0.0001.
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